where is use Yttrium-90 and Its Side Effect

 Yttrium-90 or Y-90 is a commonly used isotope in the medical field specially in departments like nuclear medicine and radiation oncology for radiation therapy. This radioisotope is relied upon to provide a prescribed amount of radiation to a targeted area , such as a tumor. One of the most common uses of Y90 is during an internal radiation therapy called radioembolization.

Radioembolization or Transarterial Radioembolization using Y-90 involves the use of glass/ resin spheres that are filled with the isotope and placed directly into the blood supply of the liver tumor through a minimally invasive procedure. These spheres get lodged within the tumor itself. The doctors then block off the blood vessels to prevent blood flow (embolization). These Y-90 labelled spheres then get to work by radiating and destroying the tumor.

Commonly, Y-90 labelled spheres are used for the treatment of liver tumors, primary hepatocellular carcinoma (HCC) and unresectable primary colorectal cancer that has metastasized to the liver. And sometimes in the treatment of Neuroendocrine Tumors (NETs) by labelling them with somatostatin receptor analog like Dotatoc or Dotatate. This is known as Y-90 PRRT.

In some cases, doctors uses Y-90 PRRT by itself or use it along with Lutetium Therapy in an alternating kind of protocol, so that the patient receives one dose of Lutetium PRRT that’s followed by a dose of Y90, followed by Lutetium and then followed by Y-90 again. This is, what doctors call, Tandem Therapy and has proven to be effective in patients who have got large volume diseases.

Read more at USE OF YTTRIUM 90 (Y-90) AND ITS EFFECTS

Comments

Post a Comment

Popular posts from this blog

Exploring the Technological Frontiers: Unveiling the Siemens Healthineers Biograph Vision PET/CT

Introducing the groundbreaking BEYOND DIGITAL PET/CT - SIEMENS HEALTHINEERS BIOGRAPH VISION, a medical imaging system that sets new standards in precision and efficiency. In the realm of precision oncology, where even the smallest details hold immense significance, the introduction of advanced digital PET-CT has revolutionized cancer diagnosis. This state-of-the-art imaging system, the BEYOND DIGITAL PET/CT - SIEMENS HEALTHINEERS BIOGRAPH VISION, is far ahead of conventional PET-CT scans, offering a host of exceptional features that have transformed the field of oncology. Now, let's explore its remarkable benefits: The BIOGRAPH VISION boasts the world's fastest time of flight, delivering unprecedented scanning speed, reducing the time taken for comprehensive imaging. Its FlowMotion Technology ensures a seamless and continuous scanning process, enhancing patient comfort while achieving faster and more accurate results. Wholebody Dynamic Imaging capabilities allow healthcare prof
Read more

Tare Vs Tace For Hepatocellular Carcinoma and Net Patients

  The incidence of Hepatocellular Carcinoma or HCC has been increasing over the past several years and several studies have projected that the incidence of HCC will continue to rise in the coming years. Transarterial Chemoembolisation or TACE has been the initial treatment modality for HCC and has a huge body of evidence from several studies and clinical trials. Therefore, for long TACE has been a preferred treatment algorithm for unresectable HCC. However, as the experience of  Transarterial Radioembolisation or TARE  has evolved, it is playing an increasingly important role in the treatment of unrespectable HCC. Studies and trials have shown that TARE has many potential advantages over TACE and there is now substantial evidence to favor TARE over TACE. The many potential advantages of TARE when compared with TACE are as below: · Several studies have shown a statistically significant overall survival advantage with TARE as compared to TACE. · TARE has better health-related quality-of-
Read more

Everything You Need To Know About Alpha PSMA Therapy

According to the  World Cancer Research Fund , Prostate Cancer is not only one of the most common malignancy in men but also one of the most commonly occurring cancer overall. Prostate Cancer is also the fifth leading cause of death from cancer in men. Disease progression and metastatic spread signifies the beginning of a lethal form of the disease – metastatic castration resistant prostate cancer (mCRPCa). The incidence of prostate cancer increases proportionally with age, especially in men above 60 years of age. Studies have also shown that incidence of prostate cancer also depend on demographics and racial prevalence – prostate cancer has a low incidence in Asia (3-8 per 100,000 men per year), an intermediate incidence in Africa and Eastern Europe, and a higher incidence in North America and Western Europe. While conventional treatment modalities for localized prostate cancers include surgery, chemotherapy, cryotherapy, brachytherapy with radioactive seeds, and usage of external
Read more